Reproxalap Improves Ocular Redness, Tear Production, and Symptoms in a Pivotal Dry Eye Disease Chamber Trial
Authors:
Open Access
- 11 September 2025
- journal article
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (1) , 100938
Abstract
No abstract availableKeywords
Funding Information
- Aldeyra Therapeutics Inc
This publication has 29 references indexed in Scilit:
- Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field TrialOphthalmology and Therapy, 2022
- Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE TrialAmerican Journal of Ophthalmology, 2021
- Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye DiseaseAmerican Journal of Ophthalmology, 2021
- Research Questions and Outcomes Prioritized by Patients With Dry EyeJAMA Ophthalmology, 2018
- SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment ModelAdvances in Therapy, 2016
- Dry Eye in the Beaver Dam Offspring Study: Prevalence, Risk Factors, and Health-Related Quality of LifeAmerican Journal of Ophthalmology, 2014
- Allergic conjunctivitis and dry eye syndromeAnnals of Allergy, Asthma & Immunology, 2012
- Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cellsExperimental Eye Research, 2008
- Reliability and Validity of the Ocular Surface Disease IndexArchives of Ophthalmology (1950), 2000
- Oxidative reactions in the tear fluid of patients suffering from dry eyesGraefe's Archive for Clinical and Experimental Ophthalmology, 1995